841
Views
6
CrossRef citations to date
0
Altmetric
Review

Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients

, &
Pages 713-738 | Received 09 Aug 2017, Accepted 22 Mar 2018, Published online: 20 Apr 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Yoshiyuki Taoda, Shuichi Sugiyama & Takahiro Seki. (2023) New designs for HIV-1 integrase inhibitors: a patent review (2018-present). Expert Opinion on Therapeutic Patents 33:1, pages 51-66.
Read now
Francesca Lombardi, Simone Belmonti, Davide Moschese, Massimiliano Fabbiani, Alberto Borghetti, Arturo Ciccullo, Elena Visconti & Simona Di Giambenedetto. (2022) Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting. HIV Research & Clinical Practice 23:1, pages 28-36.
Read now
Arturo Ciccullo, Gianmaria Baldin, Alberto Borghetti & Simona Di Giambenedetto. (2020) Dolutegravir plus lamivudine for the treatment of HIV-1 infection. Expert Review of Anti-infective Therapy 18:4, pages 279-292.
Read now
Francesca Lombardi, Simone Belmonti, Alberto Borghetti, Arturo Ciccullo, Gianmaria Baldin, Roberto Cauda, Massimiliano Fabbiani & Simona Di Giambenedetto. (2019) Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. HIV Research & Clinical Practice 20:3, pages 92-98.
Read now
Dario Cattaneo, Amedeo Capetti & Giuliano Rizzardini. (2019) Drug–drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment. Expert Opinion on Drug Metabolism & Toxicology 15:3, pages 245-252.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.